US EditionBill Gates, PAHO consider ways to bring weight-loss drugs to lower-income countries
The Gates Foundation and PAHO target obesity in low-income countries where 70% of one billion obese people live, aiming to lower costs as patents expire and generics emerge.
- The Gates Foundation and the Pan American Health Organization are exploring ways to make weight-loss drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro more accessible in lower-income countries.
- About 70% of the roughly one billion people with obesity live in low and middle‑income countries that may struggle to afford treatment, while PAHO criticised manufacturers over cost and availability, and is exploring ways to expand access to weight-loss drugs.
- This year, semaglutide’s patents expire in China and India, with generic makers developing low-cost copies while brand‑name prescriptions cost hundreds of dollars monthly.
- PAHO is developing recommendations and plans to speak to Novo Nordisk, Eli Lilly and generic makers within weeks as its fund could bulk-buy drugs and ease regulatory approvals for 35 member states.
- The Gates Foundation could support clinical trials and leverage its work with Hetero to expand access, entering obesity programs as a new focus beyond deadly diseases.
10 Articles
10 Articles
Bill Gates, PAHO consider ways to bring weight-loss drugs to lower-income countries
The Gates Foundation and the Pan American Health Organization are both working on ways to make weight-loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Mounjaro more accessible in lower-income countries, the global health groups told Reuters.
Bill Gates, PAHO consider ways to expand access to Wegovy and Mounjaro in low-income countries
The Gates Foundation and the Pan American Health Organization are both working on ways to make weight-loss drugs like Novo Nordisk's (NVO) Wegovy and Eli Lilly's (NYSE:LLY) Mounjaro more accessible in lower-income countries.
Gates Foundation and PAHO Tackle Global Accessibility of Weight-Loss Drugs
The Gates Foundation and the Pan American Health Organization are working to improve access to weight-loss drugs like Wegovy and Mounjaro in lower-income countries. Efforts include creating cheaper versions and conducting trials. The goal is to make these effective, though costly, treatments more widely available.
Coverage Details
Bias Distribution
- 78% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
